StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ProQR Therapeutics's price to sales ratio was 6.6× on Nov 11, 2026, against 13.5× a year earlier. Over the last 5 years it ranged from 5.6× to 79.3×, with a median of 16.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.6×−5.0
2025Dec 31, 202511.5×−0.2
2024Dec 31, 202411.7×−24.0
2023Dec 29, 202335.7×−43.5
2022Dec 30, 202279.3×–

More ProQR Therapeutics figures

See a number that looks wrong?